Table 2.
Comparison of baseline characteristics between the training set and the test set.
| Characteristic | Training set (n = 849) | Test set (n = 286) | P value | |
|---|---|---|---|---|
| Age (years) | 63.08 ± 13.34 | 62.74 ± 13.02 | 0.708 | |
| NAR | 1.75 ± 0.37 | 1.75 ± 0.38 | 0.884 | |
| Complement C3 (g/L) | 1.13 ± 0.20 | 1.15 ± 0.22 | 0.166 | |
| Complement C4 (g/L) | 0.38 ± 0.12 | 0.39 ± 0.12 | 0.698 | |
| Globulin (g/L) | 26.33 ± 3.65 | 26.18 ± 3.54 | 0.530 | |
| HDL (mmol/L) | 1.28 ± 0.35 | 1.30 ± 0.35 | 0.538 | |
| VZV-IgA (g/L) | 2.37 ± 0.97 | 2.45 ± 1.10 | 0.232 | |
| VZV-IgG (g/L) | 13.86 ± 3.69 | 13.47 ± 3.40 | 0.109 | |
| LDL (mmol/L) | 2.76 ± 0.89 | 2.77 ± 0.91 | 0.964 | |
| Neutrophil percentage (%) | 63.00 ± 12.18 | 64.16 ± 12.04 | 0.959 | |
| Albumin (g/L) | 36.46 ± 3.48 | 36.44 ± 3.17 | 0.091 | |
| Eosinophil percentage (%) | 1.77 ± 1.98 | 1.59 ± 2.03 | 0.682 | |
| Time to treatment (days) | 6 (4, 10) | 6 (4, 10) | 0.997 | |
| Eosinophil count (×109/L) | 0.07 (0.01, 0.13) | 0.06 (0.01, 0.13) | 0.441 | |
| hs-CRP (mg/L) | 0.5 (0.5, 3.7) | 0.7(0.5,3.2) | 0.540 | |
| WBC (×109/L) | 5.4 (4.4, 6.7) | 5.4(4.4,6.75) | 0.996 | |
| Lymphocyte count (×109/L) | 1.38 (1, 1.82) | 1.31(0.91,1.755) | 0.140 | |
| Monocyte count (×109/L) | 0.42 (0.31, 0.55) | 0.41(0.3,0.535) | 0.305 | |
| Neutrophil count (×109/L) | 3.31(2.53, 4.48) | 3.46(2.54,4.67) | 0.476 | |
| NLR | 2.4(1.61,3.8925) | 2.6(1.63,4.07) | 0.138 | |
| CLR | 0.58(0.28,2.695) | 0.67(0.3,2.835) | 0.410 | |
| SIRI | 0.95 (0.6, 1.52) | 1.08 (0.65, 1.72) | 0.098 | |
| NSE (ng/mL) | 9.55 (8.16, 10.87) | 9.35 (8.35, 10.75) | 0.554 | |
| Creatinine (μmol/L) | 62 (53, 74) | 60 (51, 72.5) | 0.136 | |
| VZV-IgM (g/L) | 0.82 (0.53, 1.21) | 0.81 (0.54, 1.285) | 0.450 | |
| Sex, n (%) | Male | 385 (74.8) | 130 (25.2) | 0.925 |
| Female | 465 (75) | 155 (25) | ||
| NRS score, n (%) | 0 | 1 (100) | 0 (0) | 0.448 |
| 1 | 52 (66.7) | 26 (33.3) | ||
| 2 | 243 (77.4) | 71 (22.6) | ||
| 3 | 173 (72.4) | 66 (27.6) | ||
| 4 | 155 (76.4) | 48 (23.6) | ||
| 5 | 112 (79.4) | 29 (20.6) | ||
| 6 | 49 (70) | 21 (30) | ||
| 7 | 39 (76.5) | 12 (23.5) | ||
| 8 | 18 (72) | 7 (28) | ||
| 9 | 7 (58.3) | 5 (41.7) | ||
| 10 | 1 (100) | 0 (0) | ||
| Prodromal pain, n (%) | No | 570 (75.5) | 185 (24.5) | 0.506 |
| Yes | 280 (73.7) | 100 (26.3) | ||
| Rash location, n (%) | Cephalic-facial | 258 (75.2) | 85 (24.8) | 0.420 |
| Thoracodorsal | 251 (77.2) | 74 (22.8) | ||
| Lumbabdominal | 163 (73.4) | 59 (26.6) | ||
| Cervicoscapular | 41 (66.1) | 21 (33.9) | ||
| Upper limb | 51 (79.7) | 13 (20.3) | ||
| Lower limb | 86 (72.3) | 33 (27.7) | ||
| Hypertension, n (%) | No | 522 (74.9) | 175 (25.1) | 0.998 |
| Yes | 328 (74.9) | 110 (25.1) | ||
| Diabetes, n (%) | No | 724 (75.1) | 240 (24.9) | 0.693 |
| Yes | 126 (73.7) | 45 (26.3) | ||
| Malignancy, COPD or CKD, n (%) | No | 730 (74.4) | 251 (25.6) | 0.351 |
| Yes | 120 (77.9) | 34 (22.1) | ||
| Antidepressant or anxiolytic medication use, n (%) | No | 816 (74.7) | 276 (25.3) | 0.519 |
| Yes | 34 (79.1) | 9 (20.9) | ||
| Anxiety or depression, n (%) | No | 832 (74.8) | 281 (25.2) | 0.449 |
| Yes | 18 (81.8) | 4 (18.2) | ||
| Sleep disorder, n (%) | No | 394 (74.5) | 135 (25.5) | 0.766 |
| Yes | 456 (75.2) | 150 (24.8) | ||
| Immunosuppressive status, n (%) | No | 807 (75) | 269 (25) | 0.715 |
| Yes | 43 (72.9) | 16 (27.1) | ||